TEL AVIV, Israel, March 31, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has priced an underwritten public offering of approximately 29.4 million American Depositary Shares ("ADSs"), each representing one (1) of its ordinary shares, at a public offering price of $0.85 per ADS for gross proceeds of $25 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioLineRx. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on April 5, 2017, subject to customary closing conditions. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional approximately 4.4 million ADSs at the public offering price. BioLineRx anticipates using the net proceeds from the offering to fund a number of clinical trials, including for BL-8040 and AGI-134, and for working capital and general corporate purposes. JMP Securities acted as sole book-running manager for the offering. H.C. Wainwright & Co., LLC acted as lead manager. Maxim Group acted as co-manager. The ADSs will be issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission ("SEC"). A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement, copies of which may be obtained, when available, from JMP Securities LLC, 600 Montgomery Street, Suite 100, San Francisco, California 94111, Attention: Prospectus Department, or by telephone: (415) 835-8985. About BioLineRx BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.